DRMA Stock Summary and Trading Ideas (Dermata Therapeutics | NASDAQ:DRMA)

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

Dermata Therapeutics trades on the NASDAQ stock market under the symbol DRMA.

As of June 4, 2026, DRMA stock price declined to $1.25 with 62,259 million shares trading.

DRMA has a beta of -2.79, meaning it tends to be less sensitive to market movements. DRMA has a correlation of 0.02 to the broad based SPY ETF.

DRMA has a market cap of $5.03 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, DRMA traded as high as $31.35 and as low as $.57.

DRMA has outperformed the market in the last year with a return of +77.5%, while the SPY ETF gained +28.2%. However, in the most recent history, DRMA shares have underperformed the stock market with its stock returning +7.8% in the last 3 month period and 0.0% for the last 2 week period, while SPY has returned +11.5% and +2.1%, respectively.

DRMA support price is $1.22 and resistance is $1.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DRMA shares will trade within this expected range on the day.